Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2021-148827

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul Koller, Jessica K. Altman, Mohamad Cherry, Benjamin Tomlinson, Namrata Chandhok, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Yuying Jin, Genia Su, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 1272.

https://doi.org/10.1182/blood-2021-149333

Published: 2021

Journal Articles

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141495

Published: 2020

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141409

Published: 2020

Journal Articles

CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

Hongying Zhang, MD, PhD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Taryn McLaughlin, MS, Alexey V Danilov, MD PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Stephen Howell, MD, William G Rice, PhD

Blood (2018) 132 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2018-99-117285

Published: 2018

Journal Articles

Synthetic Lethal Interaction between Apto-253 and Impaired BRCA1/2 Function

Cheng-Yu Tsai, PhD, Si Sun, MD, Hongying Zhang, MD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, William Rice, PhD, Stephen Howell, MD

Blood (2017) 130 (Supplement 1): 5000.

https://doi.org/10.1182/blood.V130.Suppl_1.5000.5000

Published: 2017

Journal Articles

APTO-253 Interaction with G-Quadruplex DNA Is Linked to Inhibition of c-Myc Expression, Induction of DNA Damage, and Generation of Synthetic Lethality in Cells with BRCA1/2 Impairment

Andrea Local, PhD, Hongying Zhang, MD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Cheng-Yu Tsai, PhD, Stephen Howell, MD, William Rice, PhD

Blood (2017) 130 (Supplement 1): 5094.

https://doi.org/10.1182/blood.V130.Suppl_1.5094.5094

Published: 2017

Journal Articles

CG '806, a Highly Potent First-in-Class Pan-FLT3/BTK Inhibitor, Targets Multiple Clusters of Kinases Operative in Diverse Subtypes of Acute Myeloid Leukemia

Hongying Zhang, MD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Cheng-Yu Tsai, PhD, Stephen Howell, MD, William Rice, PhD

Blood (2017) 130 (Supplement 1): 5063.

https://doi.org/10.1182/blood.V130.Suppl_1.5063.5063

Published: 2017

Journal Articles

CG '806, a First-in-Class Non-Covalent Pan-FLT3/BTK Inhibitor, Exerts Superior Potency Against B-Cell Malignant Cells

Hongying Zhang, MD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Cheng-Yu Tsai, PhD, Stephen Howell, MD, William Rice, PhD

Blood (2017) 130 (Supplement 1): 5200.

https://doi.org/10.1182/blood.V130.Suppl_1.5200.5200

Published: 2017

Journal Articles

Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

Hongying Zhang, MD PhD, Andrea Local, PhD, Khalid Benbatoul, Peter Folger, Susan Sheng, PhD, Luis Esquivies, PhD, Jeff Lightfoot, PhD, Avanish Vellanki, William G. Rice, PhD

Blood (2016) 128 (22): 1716.

https://doi.org/10.1182/blood.V128.22.1716.1716

Published: 2016

NARROW

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

Synthetic Lethal Interaction between Apto-253 and Impaired BRCA1/2 Function

APTO-253 Interaction with G-Quadruplex DNA Is Linked to Inhibition of c-Myc Expression, Induction of DNA Damage, and Generation of Synthetic Lethality in Cells with BRCA1/2 Impairment

CG '806, a Highly Potent First-in-Class Pan-FLT3/BTK Inhibitor, Targets Multiple Clusters of Kinases Operative in Diverse Subtypes of Acute Myeloid Leukemia

CG '806, a First-in-Class Non-Covalent Pan-FLT3/BTK Inhibitor, Exerts Superior Potency Against B-Cell Malignant Cells

Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only